Recent advances in squamous non-small cell lung cancer: Evidence beyond predictive biomarkers

Carlo Genova, Erika Rijavec, Francesco Grossi

Research output: Contribution to journalArticle

Abstract

Squamous non-small cell lung cancer (NSCLC) has always been characterized by a limited number of therapeutic options and by the lack of actionable biomarkers compared to its non-squamous counterpart. Recent clinical trials have led to the approval of new anti-neoplastic drugs available to both non-squamous and squamous NSCLC, consisting in a vascular-disrupting agent and two immune check-point inhibitors; additionally, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) is currently under evaluation by the Food and Drug Administration (FDA). While predictive molecular biomarkers have not been identified with consistency and are still highly demanded, these agents proved themselves noteworthy and can be considered a powerful addition to the available treatments for squamous NSCLC.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalExpert Review of Anticancer Therapy
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 2 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Biomarkers
United States Food and Drug Administration
Epidermal Growth Factor Receptor
Blood Vessels
Monoclonal Antibodies
Clinical Trials
Pharmaceutical Preparations
Therapeutics

Keywords

  • EGFR
  • Non-small cell lung cancer
  • PD-L1
  • suamous
  • targeted therapy
  • VEGFR

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Recent advances in squamous non-small cell lung cancer : Evidence beyond predictive biomarkers. / Genova, Carlo; Rijavec, Erika; Grossi, Francesco.

In: Expert Review of Anticancer Therapy, Vol. 16, No. 1, 02.01.2016, p. 1-4.

Research output: Contribution to journalArticle

@article{5435cef86e1e498b96bae6d39b662804,
title = "Recent advances in squamous non-small cell lung cancer: Evidence beyond predictive biomarkers",
abstract = "Squamous non-small cell lung cancer (NSCLC) has always been characterized by a limited number of therapeutic options and by the lack of actionable biomarkers compared to its non-squamous counterpart. Recent clinical trials have led to the approval of new anti-neoplastic drugs available to both non-squamous and squamous NSCLC, consisting in a vascular-disrupting agent and two immune check-point inhibitors; additionally, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) is currently under evaluation by the Food and Drug Administration (FDA). While predictive molecular biomarkers have not been identified with consistency and are still highly demanded, these agents proved themselves noteworthy and can be considered a powerful addition to the available treatments for squamous NSCLC.",
keywords = "EGFR, Non-small cell lung cancer, PD-L1, suamous, targeted therapy, VEGFR",
author = "Carlo Genova and Erika Rijavec and Francesco Grossi",
year = "2016",
month = "1",
day = "2",
doi = "10.1586/14737140.2016.1121112",
language = "English",
volume = "16",
pages = "1--4",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Recent advances in squamous non-small cell lung cancer

T2 - Evidence beyond predictive biomarkers

AU - Genova, Carlo

AU - Rijavec, Erika

AU - Grossi, Francesco

PY - 2016/1/2

Y1 - 2016/1/2

N2 - Squamous non-small cell lung cancer (NSCLC) has always been characterized by a limited number of therapeutic options and by the lack of actionable biomarkers compared to its non-squamous counterpart. Recent clinical trials have led to the approval of new anti-neoplastic drugs available to both non-squamous and squamous NSCLC, consisting in a vascular-disrupting agent and two immune check-point inhibitors; additionally, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) is currently under evaluation by the Food and Drug Administration (FDA). While predictive molecular biomarkers have not been identified with consistency and are still highly demanded, these agents proved themselves noteworthy and can be considered a powerful addition to the available treatments for squamous NSCLC.

AB - Squamous non-small cell lung cancer (NSCLC) has always been characterized by a limited number of therapeutic options and by the lack of actionable biomarkers compared to its non-squamous counterpart. Recent clinical trials have led to the approval of new anti-neoplastic drugs available to both non-squamous and squamous NSCLC, consisting in a vascular-disrupting agent and two immune check-point inhibitors; additionally, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) is currently under evaluation by the Food and Drug Administration (FDA). While predictive molecular biomarkers have not been identified with consistency and are still highly demanded, these agents proved themselves noteworthy and can be considered a powerful addition to the available treatments for squamous NSCLC.

KW - EGFR

KW - Non-small cell lung cancer

KW - PD-L1

KW - suamous

KW - targeted therapy

KW - VEGFR

UR - http://www.scopus.com/inward/record.url?scp=84955173817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955173817&partnerID=8YFLogxK

U2 - 10.1586/14737140.2016.1121112

DO - 10.1586/14737140.2016.1121112

M3 - Article

C2 - 26567561

AN - SCOPUS:84955173817

VL - 16

SP - 1

EP - 4

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 1

ER -